Evidence map›Paper›PMID 31429865›Full record

ArticleAmerican journal of hypertension2020

Augmenting Renal Lymphatic Density Prevents Angiotensin II-Induced Hypertension in Male and Female Mice.

Dakshnapriya Balasubbramanian, Catalina A Lopez Gelston, Alexandra H Lopez, Geina Iskander, Winter Tate, Haley Holderness, Joseph M Rutkowski, Brett M Mitchell

Open access · bronzeAbstract read
In one paragraph

Article in American journal of hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Hypertension: a lymphatic disease?Clinical science (London, England : 1979) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Lymphatics in Cardiovascular Physiology.Cold Spring Harbor perspectives in medicine · 2022
    Review
  20. Molecular Mechanisms Driving Lymphedema and Other Lymphatic Anomalies.Cold Spring Harbor perspectives in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dakshnapriya BalasubbramanianDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Catalina A Lopez GelstonDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Alexandra H LopezDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Geina IskanderDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Winter TateDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Haley HoldernessDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Joseph M RutkowskiDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Brett M MitchellDepartment of Medical Physiology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Texas A&M Health Science Center · US

Funding

Role of Renal Lymphatics in Blood Pressure RegulationR01DK120493 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI MITCHELL, BRETT M · 2019 to 2022
$1.6M
NIDDK NIH HHS R01 DK120493
6 · The paper itself

Abstract

backgroundRenal inflammation and immune cell infiltration are characteristic of several forms of hypertension. Our laboratory has previously demonstrated that renal-inflammation-associated lymphangiogenesis occurs in salt-sensitive and nitric-oxide-inhibition-induced hypertension. Moreover, enhancing renal lymphatic density prevented the development of these two forms of hypertension. Here, we investigated the effects of angiotensin II-induced hypertension on renal lymphatic vessel density in male and female mice.

methodsWild-type and genetically engineered male and female mice were infused with angiotensin II for 2 or 3 weeks. Isolated splenocytes and peritoneal macrophages from mice, and commercially available mouse lymphatic endothelial cells were used for in vitro studies.

resultsCompared to vehicle controls, angiotensin II-infused male and female mice had significantly increased renal lymphatic vessel density in association with pro-inflammatory immune cells in the kidneys of these mice. Direct treatment of lymphatic endothelial cells with angiotensin II had no effect as they lack angiotensin II receptors; however, angiotensin II treatment of splenocytes and peritoneal macrophages induced secretion of the lymphangiogenic growth factor VEGF-C in vitro. Utilizing our genetic mouse model of inducible renal lymphangiogenesis, we demonstrated that greatly augmenting renal lymphatic density prior to angiotensin II infusion prevented the development of hypertension in male and female mice and this was associated with a reduction in renal CD11c+F4/80- monocytes.

conclusionRenal lymphatics play a significant role in renal immune cell trafficking and blood pressure regulation, and represent a novel avenue of therapy for hypertension.

Indexed as

Angiotensin IIBlood PressureLymphangiogenesisAnimalsCells, CulturedDisease Models, AnimalEndothelial CellsFemaleHypertensionKidneyLymphatic VesselsMacrophages, PeritonealMaleMice, Inbred C57BLMice, TransgenicSpleenAngiotensin IIVascular Endothelial Growth Factor DVegfd protein, mouseangiotensin IIblood pressurehypertensionimmunitykidneylymphatics

Identifiers

PMID31429865
PMCPMC6931897
OpenAlexW2969411741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.